** Shares of drugmaker Emergent BioSolutions EBS.N rise ~2.9% to $9.68 premarket
** Emergent says it gained exclusive commercial rights to Hikma Pharmaceuticals' HIK.L opioid reversal nasal spray, Kloxxado
** Kloxxado rapidly reverses or blocks the effects of opioids, restoring normal respiration, especially when given within minutes of the first signs of an overdose
** Under the terms of the agreement, Hikma will continue to manufacture the nasal spray, while Emergent will handle distribution
** Up to last close, EBS up more than four-fold in the last 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。